EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

CD39 transforming cancer therapy by modulating tumor microenvironment

Suling Xu, Yuhan Ma, Xinyu Jiang, Qingqing Wang, Wenxue Ma

Cancer Letters · 2024-08 · 597 · 217072

DOI: 10.1016/j.canlet.2024.217072 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Suling Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang, 315020, China. Electronic address…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Neoplasms, Apyrase. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD39 is a pivotal enzyme in cancer, regulating immune response and tumor progression via extracellular ATP and adenosine in the tumor microenvironment (TME). Beyond its established immunoregulatory function, CD39 influences cancer cell angiogenesis and metabolism, opening new frontiers for therapeutic interventions. Current research faces gaps in understanding CD39's full impact across cancer types, with ongoing debates about its potential beyond modulating immune evasion. This review distills CD39's multifaceted roles, examining its dual actions and implications for cancer prognosis and treatment. We analyze the latest therapeutic strategies, highlighting the need for an integrated approach that combines molecular insights with TME dynamics to innovate cancer care. This synthesis underscores CD39's integral role, charting a course for precision oncology that seeks to unravel controversies and harness CD39's therapeutic promise for improved cancer outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentNeoplasmsApyraseHumansAnimalsAntigens, CDNeovascularization, Pathologic

Stichwörter der Autor:innen

AngiogenesisCD39ImmunoregulationMetabolic reprogrammingTherapeutic targetsTumor Microenvironment (TME)

Substanzen

ApyraseENTPD1 protein, humanAntigens, CD

Autor:innen und Institutionen

  • Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang, 315020, China. Electronic address: xusuling@nbu.edu.cn.
  • Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang, 315020, China. Electronic address: myhuwm@163.com.
  • Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang, 315020, China. Electronic address: jiangliu0319@163.com.
  • Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310058, China. Electronic address: wqq@zju.edu.cn.
  • Department of Medicine, Sanford Stem Cell Institute, and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA. Electronic address: wma@health.ucsd.edu.

Zitieren

APA

Xu, S., Ma, Y., Jiang, X., Wang, Q., & Ma, W. (2024). CD39 transforming cancer therapy by modulating tumor microenvironment. Cancer Letters, 597, 217072. https://doi.org/10.1016/j.canlet.2024.217072

Vancouver

Xu S, Ma Y, Jiang X, Wang Q, Ma W. CD39 transforming cancer therapy by modulating tumor microenvironment. Cancer Letters. 2024;597:217072. doi:10.1016/j.canlet.2024.217072

BibTeX
@article{Xu2024,
  author = {Xu, Suling and Ma, Yuhan and Jiang, Xinyu and Wang, Qingqing and Ma, Wenxue},
  title = {CD39 transforming cancer therapy by modulating tumor microenvironment},
  journal = {Cancer Letters},
  year = {2024},
  volume = {597},
  pages = {217072},
  doi = {10.1016/j.canlet.2024.217072}
}
Kostenlos starten →